The Form 4 filing, an SEC report of insider stock trades, was filed on November 17, 2026. The trade took place on November 13. Bobak R. Azamian is president, CEO and board chair of Tarsus Pharmaceuticals (TARS).
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-13 |
| Date of Latest Transaction | 2026-11-13 |
| Buy/Sell | sell |
| Transaction Count | 1 |
| Shares Transacted | 10,000 |
| Price | $80.31 |
| Total Transaction Value | $803,100.00 |
| Insider | |
| Ticker Symbol | TARS |
| Company | Tarsus Pharmaceuticals, Inc. |
| Insider Name | Azamian Bobak R. |
| Insider Title | President/CEO and Board Chair |
| Sector - Industry | Healthcare - Biotechnology |
| Holdings | |
| Total Shares Owned After Transaction | 817,991 |
| Position Size Change | 1.21% |
| Filing | |
| Filing Date | 2026-11-17 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
This was a sale of shares, reported with SEC transaction code S. The filing information lists one sale transaction.
What was the average price of the transaction?
The average sale price was $80.31 per share.
How did this transaction affect the insider's holdings?
The sale reduced reported holdings by 10,000 shares, leaving 817,991 shares owned afterward. The shares sold made up about 1.21% of the shares held before the sale.
What's the total transaction value?
The total reported value was $803,100.00 for the single sale transaction.
Are there any special circumstances around this transaction?
The available filing information includes a Rule 10b5-1 reference. This type of trading plan sets instructions in advance. The footnote text and plan details were not provided, so it is unclear whether the reference covers this specific sale. The plan's start date and trading schedule are also unknown. The reference alone does not show whether the sale met the rule's legal requirements.
For research purposes only; not investment advice.